Patents by Inventor Michael Edward O'Donnell

Michael Edward O'Donnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDE ANALOGS AS MODULATORS OF SODIUM CHANNELS
    Publication number: 20240400544
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 5, 2024
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Elizabeth Mary BECK, Robert PULLIN, Gorka ETXEBARRIA JARDI, Dean STAMOS, Yvonne SCHMIDT, Joseph PONTILLO, Stephen Andrew THOMSON, David Matthew SHAW, Nadia M. AHMAD, Lidio Marx CARVALHO MEIRELES, Sarah SKERRATT, Sara S. HADIDA RUAH, Timothy Donald NEUBERT, Dennis James HURLEY, Alexander KINTZER, Steven John DURRANT, Christopher WRAY, Anisa Nizarali VIRANI, Kiri NORTH, Reece JACQUES, Mark Thomas Miller, Jinglan ZHOU, Ronald Marcellus KNEGTEL, Ewa Iwona CHUDYK, Joanne Louise PINDER, Bruno Artur SOUSA, James DODD, Michael Edward O'DONNELL, Bhairavi GALAN, Rebecca E. STEVENS
  • N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS
    Publication number: 20240182455
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Application
    Filed: October 20, 2023
    Publication date: June 6, 2024
    Inventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
  • N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
    Patent number: 11827627
    Abstract: Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of using the compounds, pharmaceutically acceptable salts, and pharmaceutical compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: November 28, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Elizabeth Mary Beck, Steven John Durrant, Sarah Skerratt, Robert Pullin, Gorka Etxebarria Jardi, David Matthew Shaw, Nadia M. Ahmad, Christopher Wray, Anisa Nizarali Virani, Kiri North, James Dodd, Michael Edward O'Donnell, Bhairavi Galan, Ronald Marcellus Knegtel, Ewa Iwona Chudyk, Joanne Louise Pinder, Stephen Andrew Thomson, Lidio Marx Carvalho Meireles, Dean Stamos, Yvonne Schmidt, Joseph Pontillo, Sara S. Hadida Ruah, Timothy Donald Neubert, Dennis James Hurley, Jinglan Zhou
  • Substituted pyrazin-2-amines as inhibitors of ATR kinase
    Patent number: 10479784
    Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 19, 2019
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Steven John Durrant, David Kay, Ronald Marcellus Alphonsus Knegtel, Somhairle MacCormick, Michael Paul Mortimore, Michael Edward O'Donnell, Joanne Pinder, Alistair Rutherford, Anisa Nizarali Virani, Stephen Clinton Young, Philip Michael Reaper
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20190047995
    Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: April 30, 2018
    Publication date: February 14, 2019
    Inventors: Jean-Damien CHARRIER, Steven John DURRANT, David KAY, Ronald Marcellus Alphonsus KNEGTEL, Somhairle MACCORMICK, Michael Paul MORTIMORE, Michael Edward O'DONNELL, Joanne PINDER, Alistair RUTHERFORD, Anisa Nizarali VIRANI, Stephen Clinton YOUNG, Philip Michael REAPER
  • Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
    Patent number: 10005737
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: June 26, 2018
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20180155346
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Application
    Filed: June 26, 2017
    Publication date: June 7, 2018
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Christopher John Davis, Rebecca Davis, Steven John Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Marcellus Alphonsus Knegtel, Donald Middleton, Michael Edward O'Donnell, Maninder Panesar, Francoise Yvonne Theodora Marie Pierard, Joanne Pinder, David Matthew Shaw, Pierre-Henri Storck, John R. Studley, Heather Twin
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 9718827
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: August 1, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Christopher John Davis, Rebecca Davis, Steven John Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Marcellus Alphonsus Knegtel, Donald Middleton, Michael Edward O'Donnell, Maninder Panesar, Francoise Yvonne Theodora Marie Pierard, Joanne Pinder, David Matthew Shaw, Pierre-Henri Storck, John R. Studley, Heather Twin
  • METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
    Publication number: 20170073315
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
    Patent number: 9533959
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Grant
    Filed: February 15, 2016
    Date of Patent: January 3, 2017
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20160347754
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Application
    Filed: April 29, 2016
    Publication date: December 1, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Christopher John Davis, Rebecca Davis, Steven John Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Marcellus Alphonsus Knegtel, Donald Middleton, Michael Edward O'Donnell, Maninder Panesar, Francoise Yvonne Theodora Marie Pierard, Joanne Pinder, David Matthew Shaw, Pierre-Henri Storck, John R. Studley, Heather Twin
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20160311809
    Abstract: The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: April 29, 2016
    Publication date: October 27, 2016
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Steven John Durrant, David Kay, Ronald Marcellus Alphonsus Knegtel, Somhairle MacCormick, Michael Paul Mortimore, Michael Edward O'Donnell, Joanne Pinder, Alistair Rutherford, Anisa Nizarali Virani, Stephen Clinton Young, Philip Michael Reaper
  • METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
    Publication number: 20160159749
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Application
    Filed: February 15, 2016
    Publication date: June 9, 2016
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
    Patent number: 9296727
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 29, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES
    Publication number: 20150099875
    Abstract: The present invention relates to the novel regioselective syntheses of 2,4-disubstituted pyrimidines through sequential nucleophilic aromatic substitutions.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell
  • Aminopyrazines as ATR kinase inhibitors
    Patent number: 8877759
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: November 4, 2014
    Assignee: Vertex Pharnaceuticals Incorporated
    Inventors: Jean-Damien Charrier, David Kay, Somhairle MacCormick, Pierre-Henri Storck, Joanne Pinder, Michael Edward O'Donnell, Ronald Marcellus Alphonsus Knegtel, Stephen Clinton Young, Philip Michael Reaper, Steven John Durrant, Heather Clare Twin, Christopher John Davis
  • Compounds useful as inhibitors of ATR kinase
    Patent number: 8841450
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 23, 2014
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jean-Damien Charrier, Michael Edward O'Donnell, Simon Robert Everitt
  • COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE
    Publication number: 20130095193
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: wherein the variables are as defined herein.
    Type: Application
    Filed: September 4, 2012
    Publication date: April 18, 2013
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Somhairle MacCormick, Pierre-Henri Storck, Joanne Pinder, Michael Edward O'Donnell, Ronald Marcellus Alphonsus Knegtel, Stephen Clinton Young, Philip Michael Reaper, Steven John Durrant, Heather Clare Twin, Christopher John Davis